Having trouble accessing articles? Reset your cache.

FDA panel rebuffs lorcaserin

FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 9-5 that the benefit-risk profile of lorcaserin from Arena Pharmaceuticals Inc. (NASDAQ:ARNA) did not support approval to

Read the full 252 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE